At 17.8% CAGR, the Asia Pacific Glycomic Therapeutics Market is projected to be worth US$ 34.59 billion by 2028, says Business Market Insights  

According to Business Market Insights’ research, the Asia Pacific glycomic therapeutics market was valued at US$12.95 billion in 2022 and is expected to reach US$ 34.59 billion by 2028, registering an annual growth rate of 17.8% from 2022 to 2028. Wide application in various disorders followed by the development of new treatment processes and increasing research and development in the field of glycomic therapeutics are the critical factors attributed to the market expansion.                  

Glycan-based products have wide applications in the therapeutic industry, the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anemia, cancer, influenza, cataract, anti-inflammation, and various others. The glycoprotein is a type of glycan can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions. For instance, In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. In December 2021, researchers at Griffith University’s Institute for Glycomics received US$ 2.6 million funding from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics as a boost in their fight against cancer.Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions.These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the world drives the glycomics therapeutics market.

On the contrary, high cost of equipment hampers market Asia Pacific glycomic therapeutics market. 

• Based on class, the market is segmented into isolated and synthetic. The synthetic segment held 53.63% market share in 2022, amassing US$ 6.95 billion. It is projected to garner US$ 18.20 billion by 2028 to expand at 17.4% CAGR during 2022–2028.    
• Based on structure, the market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held 52.45% market share in 2022, amassing US$ 6.79 billion. It is projected to garner US$ 18.44 billion by 2028 to expand at 18.1% CAGR during 2022–2028.
• Based on indications, the market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, Gaucher’s disease, mps-1 & iv,cancer, alzheimer’s disease, influenza type a & b, and others. The influenza type a & b segment held 37.65% market share in 2022, amassing US$ 4.88 billion. It is projected to garner US$ 12.99 billion by 2028 to expand at 17.7% CAGR during 2022–2028.
• Based on mode of action, the market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held 39.40% market share in 2022, amassing US$ 5.10 billion. It is projected to garner US$ 13.44 billion by 2028 to expand at 17.5% CAGR during 2022–2028.
• Based on country, the Asia Pacific glycomic therapeutics market has been categorized into China ,Japan ,India ,Australia, South Korea and Rest of Asia Pacific. Our regional analysis states that China captured 29.25% market share in 2022. It was assessed at US$ 3.79 billion in 2022 and is likely to hit US$ 10.01 billion by 2028, exhibiting a CAGR of 17.6% during the forecast period.    

Key players dominating the Asia Pacific glycomic therapeutics market are BioMarinPharmaceuticalInc.;GenzymeCorporation(Sanofi);BayerAG;Alzheon,Inc.;GlaxoSmithKline plc.;F. Hoffmann-La Roche Ltd..

•  In May,2022; Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc. The acquisition aims to create specialty products.

• In May,2021; Alzheon, Inc. announced that it has entered into a collaboration and license agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) to develop the first clinical assay to measure neurotoxic beta-amyloid (amyloid, A?) oligomers in human cerebrospinal fluid (CSF). Under the collaboration agreement, IOCB applied Alzheon’s technology for detecting oligomers into a customized clinical assay in human CSF, to be developed by the IOCB and commercialized by Alzheon.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com